Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
University of California, Los Angeles · Hospital General Universitario Gregorio Marañón · +17 more institutions
Abstract
Background HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. Methods We did a randomised, open-label phase 3 KRISTINE trial in 68 Translational Research In Oncology centres (hospitals and specialty cancer centres in Asia, Europe, USA, and Canada). Eligible participants were aged 18 years or older with…
Citation impact
- FWCI
- 15.72
- Percentile
- 100%
- References
- 28
Authors
20- SASara A. HurvitzCorresponding
University of California, Los Angeles
- MMMiguel Martín
Hospital General Universitario Gregorio Marañón
- WFW. Fraser Symmans
The University of Texas MD Anderson Cancer Center
- KHKyung Hae Jung
Ulsan College, University of Ulsan, Asan Medical Center
- CHChiun‐Sheng Huang
National Taiwan University Hospital
Topics & keywords
- Pertuzumab
- Medicine
- Trastuzumab
- Trastuzumab emtansine
- Docetaxel
- Oncology
- Internal medicine
- Breast cancer
- Good health and well-being